Subscribe To
Mineralys therapeutics presents positive lorundrostat results from the phase 2 target-htn trial at acc.23/wcc
lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontroll...
March 4, 2023, 9:30 pm